BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 5, 2024
See today's BioWorld
Home
» Hey Jalousie: IPO Window Still Open, but Pricing ‘Fates’ Vary
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hey Jalousie: IPO Window Still Open, but Pricing ‘Fates’ Vary
Oct. 2, 2013
By
Randy Osborne
No Comments
The latest to price its initial public offering (IPO), Fate Therapeutics Inc. garnered about $39.6 million, an amount at the low end of its already-dipped target range, selling about 6.6 million shares at $6 each.
BioWorld